Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes

Lancet

Volumn 357, Issue 9262, 2001, Pages 1059-1060

  Greenberg, Peter ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL FEATURE; DISEASE COURSE; HIGH RISK POPULATION; HUMAN; MULTIDRUG RESISTANCE; MYELODYSPLASTIC SYNDROME; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 0035820316     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04306-3     Document Type: Note

References (20)

1. The myelodysplastic syndromes
2. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
3. Altered oncogene expression and apoptosis in myelodysplastic syndrome marrow cells
4. Apoptosis and its role in the myelodysplastic syndromes: Implications for disease natural history and treatment
5. The role of apoptosis, proliferation and the Bcl2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS
6. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome
7. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes
8. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes
9. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes
10. International scoring system for evaluating prognosis in myelodysplastic syndromes
11. NCCN practice guidelines for myelodysplastic syndromes
12. Expression of the multi-drug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype
13. Pharmacologic approaches to reversing multidrug resistance
14. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype
15. Frequency and clinical significance of expression of the multidrug resistance proteins MDR1, MRP1 and LRP in acute myeloid leukemia
16. Expression of multi-drug resistance-associated protein in myelodysplastic syndromes
17. Phase I/II trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia
18. Treatment of refractory/relapsed AML with chemotherapy plus the multi-drug resistance modulator PSC833 (Valspodar)
19. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: Results of a randomized study
20. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (ECOG 2995)